Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/64—One oxygen atom attached in position 2 or 6
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to 1-substituted aryl-5-trifluoromethyl-2-(1H)pyridones.
• the invention also relates to their preparation and medical use. Background technique
• Fibrosis can occur in a variety of organs or tissues, causing a decrease in parenchymal cells in organs or tissues, and an increase in fibrous connective tissue, which can eventually lead to destruction of organs or tissues and dysfunction, and even organ failure.
• extensive research has been conducted on the mechanism, diagnostic methods and control measures of organ or tissue fibrosis.
• considerable progress has been made in some aspects, but some key problems remain unresolved.
• pyridone has anti-inflammatory, antipyretic, lowering serum uric acid levels, and relieving pain.
• 1-phenyl-l-phenyl-2(lH)-pyridone (Pirfenidone) has the best activity and low toxicity.
• N-substituted2-(lH)pyridone ie, structural formula I
• N-substituted-3(1H)-pyridone N-substituted3-(lH)pyridone
• R 2 , R 3 and R 4 are all defined as methyl or ethyl.
• pirfenidone PFD
• the efficacy of pirfenidone, (pirfenidone, PFD) in anti-fibrosis has been confirmed by more in vitro and animal experiments.
• Experiments show clinical treatment in patients with renal fibrosis, pulmonary fibrosis and specific pulmonary fibrosis Among them, pirfenidone has the effect of preventing or even reversing the accumulation of ECM and preventing or even reversing the occurrence of fibrosis and scar formation (Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevented collagen accumulation in the remnant kidney in rats with partial Nephrectomy.
• Kidney Int, 1997,52 (Suppl 63): S239-243; Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med, 1999 , 159 : 1061-1069).
• the substituent R represents F, Cl, Br, I, a saturated linear hydrocarbon group, an oxo saturated linear hydrocarbon group, or a halogenated saturated linear hydrocarbon group.
• the position of the substituent group R on the benzene ring has an ortho, meta, para position and the like.
• Pirfenidone has been marketed in Japan in 2008 for indications for the treatment of pulmonary fibrosis. However, pirfenidone and its derivatives have little effect. The clinical daily dose of pirfenidone reached 2400 mg.
• WO2007053685 WO2006122154 discloses a class of compounds having p38 kinase inhibition which are useful in the treatment of fibrotic diseases. See Structure III for its structure:
• 1 1 to 4 is 11, alkyl, substituted alkyl, alkenyl, haloalkyl, nitroalkyl, hydroxyalkyl, alkoxy, phenyl, substituted phenyl, halogen, hydroxy, alkoxy
• WO2007062167 also discloses certain compounds having p38 kinase inhibition, which are also useful in the treatment of various fibrosis. Some of these structures are as follows:
• Chinese Patent No. 200710034357 also discloses that a compound compound having some of the above structures has anti-fibrotic activity, and also discloses that a compound having structure IV has anti-fibrotic activity.
• Structure IV These compounds introduce a trifluoromethyl group at the 5-position of the pyridone ring, which can improve the disadvantage of the weak action of pirfenidone. However, the strength of action of these compounds is still not high.
• German patent DE4343528 reports that a class of compounds has an insecticidal action in agriculture and has the following structural formula
• B is a heterocyclic ring such as a furan ring, an imidazole, a pyridine or a pyridone; and a compound of the formula VI is contained therein.
• Structural VI European Patent Nos. 2,590,048, EP 367,410 and EP 398,499 disclose a class of compounds which have an insecticidal action in agriculture and have the following structural formula VII.
• the Rio is 0 or 5.
• European Patent EP 21 6541 reports that a class of compounds has an insecticidal action in agriculture and has the following structural formula
• Structural formula IX It contains a class of compounds of formula X:
• European Patent EP488220 has a herbicidal action and has the following structural formula Xl ⁇
• the above compounds have various and multiple substituents in the structure, whether it is a pyridine ring or a benzene ring at the 1-position of the pyridine ring, and have a complicated structure, and there is no report on anti-fibrosis.
• A is: a hydrocarbon chain of 4 to 6 atoms, and one or two methyl groups may be substituted on the carbon chain.
• One or two carbon atoms in the carbon chain may be substituted by other atoms such as oxygen, carbonyl, and sulfur.
• R1 and R2 are: H; CN; N0 2 ; a halogen atom; OR 5 ; NR 6 R 7 ; C(0) ivR 6 R 7 ; 0-C(0)ivR 6 R 7 ; dC 6 alkyl; dC 6 haloalkyl group and the like.
• the activity of the anti-fibrotic compound is still not high. Further, since a plurality of fluorine atoms are introduced into the molecule, the compound is highly fat-soluble. At the same time, since there is no water-soluble group in the molecule, it cannot be used as a solution. Summary of the invention
• the 1-substituted phenyl-5-trifluoromethyl-2-(1H)pyridinone compound provided by the present invention has a structure of the formula (XIII).
• R1 ⁇ R4, R12 are selected from the group consisting of: H, CN, N0 2 , hydroxy, amino, halogen atom, a C 6 alkoxy group, NR 10 R U , OR 13 , C(0)R 14 , 0-C (0) R 14 R 15, C r C 6 alkyl, C r C 6 haloalkyl, C 2 -C 6 alkenyl group, a carboxyl group, carboxylic ester; wherein, R 14, R 15 is: dC An alkyl group of 6 ; R 1Q and R 11 are selected from the group consisting of: H, -C 6 hydroxyalkyl, esterified C r C 6 alkyl, C r C 6 alkoxyalkyl, or structural formula XIV;
• R1 ⁇ R4 and R12 are NR 1Q R U or ( ⁇ '( ⁇ " is - ⁇ hydroxyalkyl, C r C 6 ⁇ oxyalkyl; R 1Q and R 11 are not H;
• R5 is selected from the group consisting of: H, -C 6 alkyl, -C 6 haloalkyl, dC 6 hydroxyalkyl, esterified C ⁇ Cs hydroxyalkyl, C 2 -C 6 alkenyl;
• X is Selected from N, CH 2 ;
• Y is selected from N, 0, C;
• n is: 1-6;
• R12 is NI ⁇ R 11 or OR 13. According to an embodiment of the present invention, it is further preferred that when R12 is NR lt ⁇ R u or OR 13 , one of R1 to R4 is a halogen atom, and the rest is H. According to an embodiment of the invention, the following compounds are preferred in the invention:
• the salt may be hydrochloride, sulfate, phosphate, perchlorate, methanesulfonate, triflate, formate, acetate, propionate, butyrate, horse Acidate, succinate, trifluoroacetate, succinate, salicylate, DL-aspartate, D-aspartate, L-aspartate, DL- Glutamate, D-glutamate, L-glutamate, glycerate, succinate, stearate, DL-tartrate, D-tartrate, L-tartrate, ( ⁇ ) Mandelate, (R)-(-)mandelate, (S)-(+)-mandelate, citrate, mucate, maleate, malonate, benzoate, DL-malate, D-malate, L-malate, hemi-malate, 1-adamantane acetate, 1-adamantane carboxylate, xanthanate, sulfo
• the present invention also provides a method for synthesizing a compound of the formula XIII, which is synthesized as follows.
• a simple amino-substituted compound 5-trifluoromethyl-2(1H)pyridone is reacted with a nitro-substituted fluorobenzene, DMSO is used as a solvent, potassium carbonate is used as an acid-binding agent, and sodium iodide is used as a catalyst to obtain a nitro group.
• the substituent, the iron hydroxide hydrochloride is reduced to obtain an amino substituent, and the target product is obtained according to different compounds. See reaction formula I.
• Reaction formula I For a compound in which an amino group is bonded to a heterocyclic ring through a fatty side chain, first, a chloroalkyl heterocyclic compound is obtained by reacting a bromochloropropane with a heterocyclic compound, and then reacting with an amino substituent obtained according to the reaction formula I to obtain a target product. N-butanol is used as a solvent, sodium iodide is used as a catalyst, and microwave catalysis. See Reaction Scheme II. Reaction formula
• a hydroxyethylamino substituent is prepared according to the reaction formula I, reacted with thionyl chloride to obtain a chloroethylamino substituent, and then reacted with a heterocyclic compound to obtain a target product. See reaction formula III.
• the starting material trifluoromethylpyridone is a commercial raw material
• the above compounds can be used to prepare a broad spectrum fibrotic drug.
• the present invention is based on the above prior art, introducing a substituted amino group on the benzene ring of the pyridone 1 position, and introducing a hydrophilic group such as a hydroxyl group, a hetero ring or the like through an alkyl chain on the amino group to obtain a class.
• New pyridone compounds and their salts The activity of these compounds is also greatly increased.
• the Applicant has found that, based on 1-phenyl-5-trifluoromethylpyridone, the phenyl group is further modified, and the phenyl group is modified with a substituent amino group, and an unexpected effect is obtained, and the obtained compound has It has a relatively high pharmacological effect compared to the existing pyridone compounds. At the same time, such a heterocyclic-containing compound can be made into various salts, which is advantageous for various liquid preparations.
• the Applicant has found through experiments that the compound provided by the present invention has good pharmacological action against fibrosis as in the prior art pyridone compound, but the drug effect is obviously stronger than that of the prior art, and the highest is up to More than 60 times. Accordingly, the present invention also provides the use of a compound of formula XIII for the preparation of an anti-fibrotic medicament.
• FIG. 1 Renal pathology in Example 15 HE staining (X 200);
• the thiazole blue (MTT) method was used.
• the cells were cultured in DMEM medium containing 5% calf serum, and the cells were made into a 3 X 10 4 /ml cell suspension, and 100 ⁇ M per well was seeded in a 96-well plate. After the cells were attached, the medium containing 1% calf serum containing different concentrations of compound and flufenidone was changed, and 3 duplicate wells were set for each concentration. After 48 and 72 hours after dosing, the solution was added to each well (medium medium 5 mg/ml, filtered and stored in the dark) 100 ⁇ l, 4 hours later, MTT was aspirated, and MTT solution DMS0150 1 was added per well.
• the MTT After lOmin, the MTT is completely dissolved, and the enzyme labeling instrument measures the 0D value. Based on the inhibition rate, flufenidone and the IC 5 of the assay compound were calculated. value. Take both IC 5 . The value is determined as a multiple of the activity of the test compound and the activity of flufenidone. Then according to the multiple and IC 5 of flufenidone on a certain plate. The value is determined to determine the relative IC 5 of the compound. value.
• Compound 13 was prepared according to the method provided herein.
• Each rat was anesthetized by intraperitoneal injection of 0.15 ml/100 g of 10% chloral hydrate, and then fixed on a rat fixation plate. First soak the back skin with water, then tighten the skin, use a elbow to cut the skin to the hair, and routinely disinfect the towel.
• CMCNa powder is added to a suitable 0.9% physiological saline solution to prepare a CMCNa solution having a concentration of 0.5%, and the following groups of drugs are prepared by using 0.5% CMCNa solution as a solvent.
• Rats in each group were intraperitoneally injected with 10% chloral hydrate (0. 7_0. 9ml/100g) on the 11th day after operation, and the obstructed kidney tissue was fixed with 4% formaldehyde and embedded in paraffin. 4 ⁇ ⁇ thick sections, HE staining and Masson staining ⁇ > ( 5 ) HE staining scoring standard
• renal interstitial lesions were scored according to 8 indicators: renal tubular epithelial vacuoles Denaturation, tubular dilatation, tubular atrophy, red blood cell cast, protein cast, interstitial edema, interstitial fibrosis, interstitial inflammatory cell infiltration, and the mean value was calculated as the tubulointerstitial damage index of the specimen. Scoring Criteria References: Radford MG Jr, Donadio JV Jr, Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy . J Am Soc Nephrol, 1997, 8(2): 199-207.
• the compound 1315 mg/kg is effective in treating renal fibrosis.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Pulmonology (AREA)
• Epidemiology (AREA)
• Pyridine Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=43222160

Family Applications (1)

Country Status (7)

Cited By (3)

Families Citing this family (6)

Citations (18)

Family Cites Families (9)

• 2010
  • 2010-05-24 EP EP10780053.4A patent/EP2436670B1/en not_active Not-in-force
  • 2010-05-24 WO PCT/CN2010/073105 patent/WO2010135972A1/zh not_active Ceased
  • 2010-05-24 CN CN2010800025583A patent/CN102149682B/zh active Active
  • 2010-05-24 US US13/322,152 patent/US8426407B2/en not_active Expired - Fee Related
  • 2010-05-24 AU AU2010252447A patent/AU2010252447B2/en not_active Ceased
  • 2010-05-24 JP JP2012512188A patent/JP5583758B2/ja not_active Expired - Fee Related
  • 2010-05-24 KR KR1020117030518A patent/KR101522924B1/ko not_active Expired - Fee Related

Patent Citations (18)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events